Skip to content

Effects of exenatide on postprandial vascular endothelial function in type 2 diabetes mellitus

Effects of exenatide on postprandial vascular endothelial function in type 2 diabetes mellitus - Effects of exenatide on postprandial vascular endothelial function in type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000015699
Enrollment
15
Registered
2014-11-15
Start date
2011-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Patients with type 2 diabetes mellitus undergo a meal tolerance test to examine changes in postprandial endothelial function and changes in glucose and lipid metabolism without exenatide administratio

Sponsors

First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) age 20 to less than 80; 2) no change in oral antihyperglycemic drug therapy, lipid metabolism-improving drug therapy, or antihypertensive drug therapy during the 12 weeks preceding enrollment; and 3) ongoing treatment by diet regimen alone or by therapy with sulfonylurea, sulfonylurea plus biguanide, or sulfonylurea plus thiazolidine derivatives.

Exclusion criteria

Exclusion criteria: 1) receiving insulin therapy; 2) having diabetic ketoacidosis, nonketotic hyperosmolar coma, infection, or acute coronary syndrome; 3) being pregnant or possibly pregnant; 4) having a history of stroke or ischemic heart disease occurring within the preceding 6 months; 5) having a history of pancreatitis; and 6) having arrhythmia.

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the difference between changes in postprandial vascular endothelial function without eventide administration compared with single-dose exenatide administration.

Countries

Japan

Contacts

Public ContactKeiichi Torimoto

School of Medicine, University of Occupational and Environmental Health First Department of Internal Medicine

torimoto@med.uoeh-u.ac.jp090-603-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026